Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria.
PLoS One. 2010 Jan 15;5(1):e8722. doi: 10.1371/journal.pone.0008722.
Liver-selective thyromimetics have been reported to efficiently reduce plasma cholesterol through the hepatic induction of both, the low-density lipoprotein receptor (LDLr) and the high-density lipoprotein (HDL) receptor; the scavenger receptor class B type I (SR-BI). Here, we investigated the effect of the thyromimetic T-0681 on reverse cholesterol transport (RCT) and atherosclerosis, and studied the underlying mechanisms using different mouse models, including mice lacking LDLr, SR-BI, and apoE, as well as CETP transgenic mice.
METHODOLOGY/PRINCIPAL FINDINGS: T-0681 treatment promoted bile acid production and biliary sterol secretion consistently in the majority of the studied mouse models, which was associated with a marked reduction of plasma cholesterol. Using an assay of macrophage RCT in mice, we found T-0681 to significantly increase fecal excretion of macrophage-derived neutral and acidic sterols. No positive effect on RCT was found in CETP transgenic mice, most likely due to the observed decrease in plasma CETP mass. Studies in SR-BI KO and LDLr KO mice suggested hepatic LDLr to be necessary for the action of T-0681 on lipid metabolism, as the compound did not have any influence on plasma cholesterol levels in mice lacking this receptor. Finally, prolonged treatment with T-0681 reduced the development of atherosclerosis by 60% in apoE KOs on Western type diet. In contrast, at an earlier time-point T-0681 slightly increased small fatty streak lesions, in part due to an impaired macrophage cholesterol efflux capacity, when compared to controls.
CONCLUSIONS/SIGNIFICANCE: The present results show that liver-selective thyromimetics can promote RCT and that such compounds may protect from atherosclerosis partly through induction of bile acid metabolism and biliary sterol secretion. On-going clinical trials will show whether selective thyromimetics do prevent atherosclerosis also in humans.
已报道肝选择性甲状腺刺激剂可通过肝脏诱导低密度脂蛋白受体 (LDLr) 和高密度脂蛋白 (HDL) 受体;清道夫受体 B 类 I 型 (SR-BI) ,有效地降低血浆胆固醇。在这里,我们研究了甲状腺刺激剂 T-0681 对胆固醇逆向转运 (RCT) 和动脉粥样硬化的影响,并使用不同的小鼠模型研究了潜在的机制,包括缺乏 LDLr、SR-BI 和 apoE 的小鼠,以及 CETP 转基因小鼠。
方法/主要发现:T-0681 治疗在大多数研究的小鼠模型中一致促进胆汁酸生成和胆汁胆固醇分泌,从而显著降低血浆胆固醇。在用小鼠巨噬细胞 RCT 测定法进行研究时,我们发现 T-0681 可显著增加巨噬细胞衍生的中性和酸性固醇的粪便排泄。在 CETP 转基因小鼠中未发现对 RCT 的积极影响,这很可能是由于观察到血浆 CETP 质量下降所致。在 SR-BI KO 和 LDLr KO 小鼠中的研究表明,肝 LDLr 对于 T-0681 对脂质代谢的作用是必需的,因为该化合物在缺乏该受体的小鼠中对血浆胆固醇水平没有任何影响。最后,在西方饮食的 apoE KOs 中,长期用 T-0681 治疗可使动脉粥样硬化的发展减少 60%。相比之下,与对照组相比,在较早的时间点,T-0681 由于巨噬细胞胆固醇流出能力受损,略微增加了小的脂肪条纹病变。
结论/意义:目前的结果表明,肝选择性甲状腺刺激剂可促进 RCT,并且这些化合物可能通过诱导胆汁酸代谢和胆汁胆固醇分泌来部分保护免受动脉粥样硬化的侵害。正在进行的临床试验将显示选择性甲状腺刺激剂是否也能预防人类的动脉粥样硬化。